New device detects deadly lung disease

The lateral-flow device (LFD) detects invasive pulmonary aspergillosis, a notoriously difficult to diagnose disease caused by the fungus Aspergillus. Credit: University of Exeter

A scientist from the University of Exeter has developed a simple, cheap and highly accurate device for diagnosing a frequently fatal lung disease which attacks immune deficient individuals such as cancer patients and bone marrow transplant recipients.

The lateral-flow device (LFD), created by Professor Chris Thornton, detects invasive pulmonary aspergillosis, a notoriously difficult to diagnose disease caused by the fungus Aspergillus.

Invasive aspergillosis is a leading cause of death in and patients, accounting for more than 200,000 life-threatening infections each year, with an associated mortality rate of up to 90%.

The new device – which resembles a pregnancy test but uses a small blood sample – will cost health authorities just £10 per test and will fit into routine hospital practices. It will potentially reduce the high rates of mortality and morbidity associated with the disease and enable better use of costly and toxic antifungal drugs.

Professor Thornton, of Biosciences, said: "Individuals with invasive are often suffering from complex medical conditions and the symptoms, which include raised temperature, breathlessness, chest pain and fatigue, could be attributable to a number of other conditions. At present, it can take several days to identify the disease correctly due to the lack of accurate diagnostic tests, and the patient's health deteriorates significantly in the absence of appropriate treatment.

"The low cost, speed, ease-of-use and compatibility of the new device with standard hospital procedures means that the disease can be quickly and accurately monitored at the point-of-care using a simple blood test or with fluids collected during lung biopsy."

Professor Thornton and colleagues have published a number of clinical studies with hospitals in London, Germany, Austria and elsewhere in mainland Europe.

There is also an ongoing trial with leukaemia patients at the Royal Devon and Exeter Hospital under the care of Consultant Haematologist Dr Paul Kerr. He said: "We at the Exeter Leukaemia Unit are very proud to work with Dr Thornton and his team on this project; diagnosing this life-threatening infection is very difficult, and can involve either subjecting the patient to unpleasant and potentially dangerous investigations, or can result in the use of expensive and toxic medication that may not always be needed. It is very exciting to think that a simple laboratory test may allow us to greatly simplify this process in the future."

With financial support from the University and Angel funders, a spin-out company called ISCA Diagnostics Ltd was established to enable commercialisation of the test. Global marketing and distribution of the device is delivered through ISCA's partner company OLM Medical.

The lateral flow device will be being used in hospitals around the world from August. The test uses a highly specific monoclonal antibody to detect a diagnostic marker of active Aspergillus infection, meaning that doctors can more precisely identify patients developing the disease.

This success is a visible example of how University bench-to-bedside Research & Development can deliver commercial impact through academic, industry and private investor partnerships.

The work has received funding from the US National Institutes of Health, HEIF, private investors, and a global pharmaceuticals company.

Professor Thornton is a fungal immunologist with a specialist interest in hybridoma technology and immunodiagnostics. His recent research has concentrated on human infections by opportunistic fungal pathogens and their rapid detection using monoclonal antibodies.

add to favorites email to friend print save as pdf

Related Stories

Manchester researchers world first in complex genetics testing

Feb 12, 2014

A grandfather-of-three from Tameside is helping University of Manchester researchers become the first in the world to assess all the genetic links with Chronic Pulmonary Aspergillosis (CPA) - a debilitating fungal lung infection ...

Baker's yeast protects against fatal infections

Aug 10, 2011

Injecting mice with simple baker's yeast protects against the fatal fungal infection, aspergillosis, according to research published in the Journal of Medical Microbiology. The work could lead to the development of a huma ...

Recommended for you

Sierra Leone streets deserted as shutdown begins

4 hours ago

Sierra Leone's normally chaotic capital resembled a ghost town on Friday as residents were confined to their homes for the start of a three-day lockdown aimed at halting the deadly Ebola epidemic.

Sierra Leone launches controversial Ebola shutdown

6 hours ago

Sierra Leone on Friday launched a controversial three-day shutdown to contain the deadly spread of the Ebola virus, as the UN Security Council declared the deadly outbreak a threat to world peace.

Cooling of dialysis fluids protects against brain damage

19 hours ago

While dialysis can cause blood pressure changes that damage the brain, cooling dialysis fluids can protect against such effects. The findings come from a study appearing in an upcoming issue of the Journal of the American So ...

Two Ebola vaccines to be tested in Switzerland

19 hours ago

Clinical trials of two experimental vaccines against the deadly Ebola virus are due to begin soon in Switzerland, the country's Tropical and Public Health Institute said on Thursday.

User comments